Ravulizumab for Delayed Graft Function After Kidney Transplant
This study is testing a drug called ravulizumab to see if it can help adult kidney transplant patients who are at high risk for Delayed Graft Function (DGF). DGF means the new kidney doesn't work well right away and dialysis might still be needed. You could be eligible if you are 18 or older, have kidney disease requiring dialysis, and are receiving a kidney from a specific type of deceased donor. The study will compare ravulizumab to a placebo (an inactive substance) to see if ravulizumab helps patients get off dialysis sooner after their transplant. The study aims to enroll 450 participants.
- Study design
- This is a double-blind, randomized, placebo-controlled study, meaning neither you nor your doctors will know if you are receiving ravulizumab or a placebo. About 450 participants will be enrolled.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be followed for up to 90 days after your transplant to see how long it takes to no longer need dialysis.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
At a glance
Conditions
Where it's being run
130 sites across 43 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Time to Freedom from DialysisThrough 90 days post-transplant